Oruvail and Overdose - a phase IV clinical study of FDA data

Summary:

Overdose is reported as a side effect among people who take Oruvail (ketoprofen), especially for people who are female, 60+ old, also take Enbrel, and have Empty sella syndrome.

The phase IV clinical study analyzes which people have Overdose when taking Oruvail. It is created by eHealthMe based on reports of 645 people who have side effects when taking Oruvail from the FDA, and is updated regularly.

What is Oruvail?

Oruvail has active ingredients of ketoprofen. eHealthMe is studying from 648 Oruvail users. Check the latest studies of Oruvail.

What is Overdose?

Overdose is found to be associated with 2,219 drugs and 2,471 conditions by eHealthMe. Check the latest studies of Overdose.

On Jul, 10, 2026

645 people reported to have side effects when taking Oruvail.
Among them, 131 people (20.31%) have Overdose.

Among these 131 people:

* Approximation only. Some reports may have incomplete information.

Do you take Oruvail and have Overdose?

- Check whether Overdose is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oruvail:

Oruvail (648 reports)

Overdose treatments and more:

Overdose (229,245 reports)

How severe was Overdose and when was it recovered:

Overdose in Oruvail

Expand to all the drugs that have ingredients of ketoprofen:

Overdose and drugs with ingredients of ketoprofen (731 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Oruvail:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Overdose:

Overdose (2,219 drugs)

Browse all the conditions that are associated with Overdose:

Overdose (2,471 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ketoprofen (the active ingredients of Oruvail) and Oruvail (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.